Last reviewed · How we verify
NCT06216587
BLa80 Improve Drinkers' Gut Microbiota
NA trial testing BLa80 in Alcohol Drinking, Adult Disease in 120 participants. Status unknown.
25 June 2024
Quick facts
| Lead sponsor | Wecare Probiotics Co., Ltd. |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 120 |
| Start date | 20 March 2024 |
| Primary completion | 25 June 2024 |
| Estimated completion | 14 July 2024 |
Drugs / interventions tested
- BLa80
Conditions studied
- Alcohol Drinking, Adult Disease — all drugs for Alcohol Drinking, Adult Disease →
Sponsor
Wecare Probiotics Co., Ltd. — full company profile →
Who can join
Adults 18 to 65, any sex, with Alcohol Drinking, Adult Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to understand the effects of the probiotic BLa80 on the gut health of people who drink alcohol regularly. We want to find out if this probiotic can help improve the health of the digestive system in those who consume alcohol. The main questions we aim to answer are: Does BLa80 positively change the composition of gut bacteria in alcohol consumers? Participants in this study will: Be randomly assigned to one of two groups. One group will receive the probiotic BLa80, and the other group will receive a placebo (a substance with no active therapeutic effect). Take their assigned treatment for a specified period, as directed by the study protocol. Undergo regular health checks and provide feceal samples for analysis to see how their gut bacteria might have changed during the study. This study is important because it explores whether a specific type of probiotic can help protect or improve gut health in people who drink alcohol, potentially offering a new way to support digestive health.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06216587
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of BLa80
Trials testing the same drug.
- NCT07287306 — Effects of BLa80 and LRa05 on the Gut Microbiota Metabolite Profile of Healthy Individuals · NA · recruiting
- NCT06107049 — the Effect of Probiotic on Sleep Quality Management · NA · completed
Other Wecare Probiotics Co., Ltd. trials
Trials by the same sponsor.
- NCT07529457 — Akk09 in Adults With Constipation · NA · not yet recruiting
- NCT07507955 — Probiotics for Constipation Relief in Adults · NA · not yet recruiting
- NCT07462494 — Probiotic Intervention in Constipation · NA · not yet recruiting
- NCT07462481 — Probiotic Improve Constipation · NA · recruiting
- NCT07507929 — Probiotic for Weight Management in Overweight and Obese Adults · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06216587 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Wecare Probiotics Co., Ltd.
- Last refreshed: 22 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06216587.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing